Background The prognosis of patients with primary pulmonary hypertension (PPH) remains a major problem for the planning and assessment of therapeutic interventions. The objectives of this study were (1) to characterize mortality in a Mexican population of patients with PPH and to investigate factors associated with survival and (2) to test the applicability in this population of the prognostic equation proposed by the US National Institutes of Health study on PPH.
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Methods and Results A dynamic cohort of patients with PPH at our institution were enrolled between June 1977 and August 1991 and prospectively followed at regular intervals through September 1992. Measurements at diagnosis included hemodynamic and pulmonary function variables in addition to information on demographic data and medical history. The response to vasodilator treatment was also analyzed. The estimated median survival of the group was 4.04 years (95% confidence interval, 2.98 to 5.08 years). Variables associated with poor survival (univariate analysis) included an elevated mean right atrial pressure, a decreased cardiac index, and a decreased mixed venous P02. A reduced forced vital capacity and the absence of vasodilator treatment were also associated with poor survival. A P rimary pulmonary hypertension (PPH) is an uncommon disease that affects predominantly young and productive people.'-3 Although important conceptual advances and information about the pathogenesis, [3] [4] [5] [6] histopathology,3'7-12 characterization,1-3"13'14 and management3 '12"13"15-19 of PPH have been generated in the past decade, many questions remain to be answered. For instance, studies evaluating the effect of therapeutic interventions in PPH are limited by the scarcity of information on certain aspects of the natural history, particularly those regarding the immediate and long-term prognosis of the disease. Part of the reason for the lack of complete knowledge in this regard is explained precisely by the fact that PPH is a rare entity, with only several hundred patients worldwide. One of the major contributions of the multicenter study of the US National Institutes of Health (NIH) registry on PPH1420 was to recognize a highly variable clinical course of the disease. Although a typical mean survival of 2 to 3 years from the time of diagnosis has multivariate Cox proportional-hazards regression analysis was used to assess the adjusted hazard ratios, hence the relative contributions of the variables controlling for confounding. Reduced forced vital capacity and cardiac index and increased right atrial pressure were still significantly associated as risk factors for survival in patients with PPH. Survival as computed by the equation correlated with real survival of PPH patients with positive predictive values of 87%, 91%, and 89% at 1, 2, and 3 years, respectively. The equation, however, was relatively unable to predict deaths in our population, in part because of the strict limits of poor prognosis.
Conclusions Mortality in PPH is largely associated with hemodynamic variables that assess right ventricular function. The proposed prognostic equation had a high sensitivity and a relatively low specificity to predict survival in our PPH population. To improve this specificity it may be necessary to increase the limits of poor prognosis as defined by the equation. (Circulation. 1994; 89:1733 -1744 Key Words * circulation * pulmonary heart disease . vasodilation * hypertension been described,23"2"3 it is now clear that there are patients with PPH for whom survival exceeding 5 to 10 years is well documented;3"13'1820-22 even spontaneous regression of the disease, although uncommon, has been described. 23 '24 Within the context of this variable clinical course, it is not surprising that the prognosis as well as the effect of therapeutic interventions on survival would be difficult to define. In the past decade, more systematic and prospective follow-up studies have started, and more information regarding the natural history of PPH is now available. A continued search for a clinical and/or hemodynamic marker of prognosis therefore seems appropriate.
At our institution, the availability of vasodilating drug testing since 1977 has led to the referral of a large number of patients with PPH for consideration for medical treatment. We report here part of the experience derived from the continued study of 61 patients with PPH in the past 15 years. We describe their clinical and hemodynamic characteristics at entry as well as their evolution over the years. We analyzed the clinical and hemodynamic determinants associated with their mortality and the applicability in our population of the equation to predict prognosis of patients with PPH recently proposed by the NIH multicenter study on PPH.20 1991 and who were prospectively followed through September 1992. The diagnostic and therapeutic approaches have followed strict clinical and hemodynamic criteria that have remained basically unchanged over the years. As in other studies,331314 every patient had a thorough workup, including clinical history and physical examination, laboratory tests, chest radiograph, ECG, pulmonary function tests, echocardiography, radionuclide perfusion lung scan, and cardiac catheterization. All the procedures were approved by our local committee for clinical investigation; they were explained to the patients or to their parents, and their consent was obtained.
Criteria used to establish the diagnosis of PPH included the presence of elevated mean pulmonary artery pressure (PAP) >22 mm Hg at rest, a normal pulmonary capillary wedge pressure (PCWP) when measurable, and the absence of other diseases known to cause or to be associated with secondary pulmonary hypertension.3'13'14 Particular care was taken to exclude patients with evidence of pulmonary thromboembolic disease, congenital heart disease or acquired valvular or myocardial disease, obstructive and/or restrictive lung disease, parasitic disease involving the lungs, liver cirrhosis, clearly defined collagen vascular disease, or the antiphospholipid syndrome.
Hemodynamic Measurements
Our procedure for cardiac catheterization at rest has been described elsewhere.2526 In brief, cardiac output (CO) was measured in triplicate by the thermodilution method, and pressures were obtained with a Swan-Ganz catheter. This catheter is also used for sampling mixed venous Po2 (Pvo2). In most cases, the brachial artery was also cannulated with a Cournand-Potts needle for systemic pressure recording and arterial blood sampling. Standard formulas were used to calculate cardiac index, stroke volume index (SVI), indexed pulmonary vascular resistance (PVRI), and systemic resistance (R). We also calculated the ratio of pulmonary to systemic arterial resistance (RP/RJ).
Vasodilating Drug Testing and Long-term Treatment
Most of the patients in this study have had at least one acute trial with vasodilators. Before testing, we tried to ensure a steady state by waiting about 15 minutes to obtain the baseline hemodynamic values. Then the hemodynamic response to oxygen breathing (Fio2 1.0) was evaluated in most patients. The protocol for vasodilating testing has remained basically unchanged, but the selected vasodilating drug for the acute challenge has changed over the years. The drugs we used were isoproterenol 3 to 5 jig infused into the pulmonary artery in 1 minute,26 hydralazine 0.33 mg/kg infused into the pulmonary artery over 3 minutes,25 and nifedipine 10 to 20 mg sublingually.27 On the basis of the hemodynamic response to the acute vasodilating trial, we separated the patients into two groups: responders and nonresponders. The criteria for an acute favorable response to vasodilators included (1) a significant decrease in PAP or PVRI (>20% from baseline), (2) a predominant pulmonary vasodilator response as assessed by the decrease in the RP/RS ratio, and (3) absence of a deleterious effect on pulmonary gas exchange. Only when the above criteria were met was the patient considered for vasodilating drug treatment. In the majority of the patients the short-term response to the oral medication was evaluated on the ward and reassessed again 1 week later. After evaluation of a satisfactory acute and short-term response, the patients were considered for long-term vasodilator treatment. Over the years, most of the initial patients on treatment have been changed to a different vasodilating drug, first from sublingual isoproterenol to oral hydralazine and then from hydralazine to oral nifedipine. The decision for the change in drug treatment was always based on the results of a new hemodynamic study. At present, most of the patients on chronic vasodilator treatment in our study receive nifedipine, and the hemodynamic and clinical effects of the drug have been reassessed repeatedly in the surviving patients.
Other Therapeutic Measures
We did not use routine anticoagulant therapy in our patients until recent years. Digitalis was used in rare cases, and mild diuretic therapy was used for the treatment of symptomatic right-sided cardiac failure.
Analysis
In the present study, (1) we analyzed the clinical and hemodynamic characteristics of our patients at entry in the whole group (n=61) and separately in the groups of patients with (n=28) and without (n=32) long-term vasodilating treatment as well as in the group of patients who either died (n=22) or survived more than 5 years (n=22). (2) For the survival analysis we used the initial diagnostic catheterization as an index for determining survival. One patient who died during initial catheterization was excluded from the survival analysis because this was considered a prevalent rather than an incident case. The Kaplan-Meier method was used to estimate overall survival distribution.28 Univariate analysis based on the proportional-hazards model28 was used to examine the relation between survival and selected demographic, medicalhistory, pulmonary-function, laboratory, and hemodynamic variables measured at initial catheterization. Results are expressed as hazard ratios with 95% confidence intervals (CIs). A(x,y,z) =e (0 007325X)' i(00526y) --(0.3275) where x is the mean PAP, y is the mean right atrial pressure (RAP), and z is the cardiac index. All values were obtained at initial catheterization. The probability to survive 1, 2, and 3 years would be then given by P(1)=.75A P(2) =.65A P(3)= 55A
By using this formula, we calculated and compared the projected survival with real survival both in the whole group of patients and separately in the groups with and without treatment.
For the rest of the statistical analysis we used paired and unpaired t tests, linear regression, and one-way ANOVA and Tukey's test. All values are expressed as mean± SD. A value of P<.05 was accepted for significance in all comparative analyses.
Results

Demographic Characteristics
The mean age of the patients with PPH entered into the study is 22.6±11 years, and women are predominant. The overall female-to-male ratio was 3.06:1. The age distribution of patients with this disease showed the highest frequency in the third decade (22 of 46) for female patients and the first and second decades for male patients (9 of 15 patients). All the patients are Hispanic. Nineteen of the 61 patients were born and raised in and are residents of Mexico City (2240 m above sea level). The rest of the patients were referred to us from different parts of the country. pattern was more difficult because the interobserver variation in interpretation was wide; however, in none of the studies was there evidence for lobar or singlesegment defect.
Results of an antinuclear antibody test were positive in 13% of the patients in whom it was determined. The mean hemoglobin and hematocrit levels of the group were 16± 1.8 g/dL and 49±6.5%, respectively. The total platelet count was normal.
Pulmonary Function
Pulmonary function tests could be performed in the PPH patients who were >10 years old, and the mean The hemodynamic response to the acute administration of vasodilators could be assessed in 48 of the 61 patients. The reasons for not performing an acute vasodilator trial in the 13 remaining patients were baseline systemic arterial hypotension (8 patients), severe right ventricular dysfunction (ie, RVEDP >20 mm Hg) (4 patients), and the death of 1 patient during the catheterization procedure before drug testing. The results of the acute vasodilating trial are shown in Table  2 . Twenty of the 48 patients did not respond to the vasodilating drug (nonresponders). In most of these patients neither the PAP nor the PVRI was significantly decreased by the administration of the drug. For analysis, the group of responders (n=28) has been further divided into two groups according to the type of response to the vasodilator: the group of patients with a complete response (n= 15), in whom there was a significant decrease (>20%) in both PAP and PVRI after the administration of the drug, and the group of patients with a partial response (n= 13), which includes those patients in whom only a decrease in PVRI was significant. From Table 2 it can be observed that the nonresponder patients have a significantly higher (P< .05) baseline PAP and PVRI than their counterpart responder patients. Adverse Consequences Eight of the 61 patients had mild transient episodes of systemic hypotension not related to drug testing. In another 5 patients the episode of hypotension was related to the administration of the vasodilating drug. In these patients the episode was more prolonged and required intravenous infusion of fluids. Unfortunately, as mentioned before, one of the patients in this series died during the catheterization procedure before the drug testing. This patient had one of the highest levels of RVEDP (24 mm Hg), and as soon as the Swan-Ganz catheter was placed in the pulmonary artery and CO was measured, she suffered severe sinus bradycardia immediately followed by irreversible cardiac arrest. As a result of this unfortunate experience, we decided not to continue any catheterization procedure once a critical right ventricular dysfunction is demonstrated.l6 Treatment With Vasodilators Based on the results of the acute and short-term vasodilating trial, 28 patients have received this vasodilator treatment on a long-term basis. Thirty-two of the 60 patients compose the group without vasodilator treatment. This group includes both the 20 nonresponder patients and 12 of the patients who did not have an acute vasodilating trial. The pulmonary function variables and hemodynamic findings at entry in the groups with and without long-term vasodilator treatment are shown in Table 3 Fig 1) . In the group with long-term vasodilator treatment, we further calculated survival times for two separate groups according to the hemodynamic (ie, partial or complete) response to vasodilator. Although the median survival times were not different between these two groups, the short-term prognosis (at 2 years) appears to be better in the group with complete response (see Fig 2) .
Of (Fig 3) ; however, there was a closer correlation between predicted and real survival in the group without vasodilator treatment (Fig 4) . Discussion Until recent years most of the clinical studies on PPH had dealt with series either of a small number of patients or with a short period of follow-up; therefore, most of the knowledge concerning clinical characteristics and natural history of the disease had been obtained from retrospective pathological studies.7 At present, however, important information in this regard has been generated by the prospective multicenter study on PPH of the NIH. In this thorough study, it was possible to recruit prospectively 187 patients from 32 different clinical centers. The clinical characterization of the disease was reported in 1987,14 and the information on survival of 194 patients with PPH diagnosed between July 1981 and December 1985 and followed through August 1988 was published in September 1991.20 Although it has a different design, our study meets two important criteria: a relatively large number of patients and a long period of follow-up. An additional feature of the present study is the fact that the diagnos- studies. From the demographic point of view, age and sex distribution are different in the two series. PPH patients in our study are younger (22.6 versus 36.4 years), and the female-to-male ratio is higher (3.06:1 versus 1.7 :1). This female-to-male preponderance in our study is the same as that found in the black population of the NIH study on PPH'4 and similar to that previously reported in other series.'1278 Overall, however, women in the third decade of life compose the group in which the disease shows the highest frequency, a finding also shown in most prior studies.1-3,8,13,14 The two series, on the other hand, are similar in regard to past medical and family history of PPH. Also, with the exception of chest pain, edema, and functional class, there are remarkable similarities regarding presenting symptoms and physical examination findings. It should be stressed that chest pain in our study refers only to that suggestive of angina (ie, exercise-related), and this might explain the lower incidence of this symptom in our population (21% versus 31%). Peripheral edema and functional classes III and IV were more frequent in the NIH study. This evidence of more severe clinical deterioration at diagnosis is in agreement with the evidence of more severe hemodynamic involvement also found in the PPH patients of the NIH study. Although PPH patients in both studies have severe pulmonary hypertension, with a similar threefold increase in mean PAP, cardiac indexes are lower (2.27 versus 3.16 L/min m2) and RAPs are higher (9 versus 7 mm Hg) in the NIH study, reflecting a more severe right ventricular dysfunction at diagnosis in this group.
In regard to laboratory findings, the prevalence of a positive antinuclear antibody test was different and lower in our study (13% versus 29%). This finding, however, may be the result of a different sensitivity of the test used for detection. 33 In regard to pulmonary function testing, Table 4 , only the group of patients with a complete response in the acute trial sustains a significant favorable long-term hemodynamic response. Also, these patients appear to have a better short-term prognosis than those who had only a partial response (see Fig 3) . The effect on survival of this type of complete response to a vasodilator has been more clearly illustrated in the recent study by Rich et al, 15 who showed an improved survival in PPH patients with the use of high doses of calcium channel blockers. Natural History
The present study also confirms the previously established knowledge that PPH is a disease with a poor prognosis. 2, 3, 8, 12, 13, 2039 The median survival of the entire group in our study is 4.04 years (95% CI, 2.98 to 5.08 years). That means that about 50% of the patients are dead at 5 years from diagnosis. This survival expectancy in our study, however, appears to be better than that reported in other series,18'21339 and it is also better than the estimated median survival of 2.8 years (95% CI, 1.9 to 3.7 years) found in the NIH registry on PPH study20 (see Fig 5) . This difference in survival between these two series may be explained by the fact that PPH patients in the NIH study (1) are older and (2) as a group, had evidence of more severe clinical and hemodynamic deterioration at diagnosis (see "Characterization of PPH"). In this regard, it is interesting to note that the baseline hemodynamic profile of the patients without treatment in our study more closely resembles that of the patients in the NIH study (see Table 3 ) and, as shown in Fig 5, similar to that of the NIH study. Accordingly, when the baseline hemodynamic profile is similar, the survival is also comparable. Despite the multivariate analysis, the design of our study does not allow assessment of the independent effect of vasodilator treatment on survival. Patients under vasodilator treatment have a better survival (see Fig 1) ; however, this group of patients also has a better hemodynamic profile at diagnosis (see Table 3 ). It would have been useful from the methodological point of view to further separate the responder patients into two subgroups, one with and the other without longterm vasodilator treatment, and to assess the long-term response. However, from the beginning of this experience, it was clear to us that responder patients with treatment showed a significant improvement in their functional status, probably as a result of the increase in cardiac output promoted by these drugs; therefore, for ethical reasons, we decided to give long-term vasodilator treatment to every patient who had a positive response in the acute trial. 40 The role of long-term anticoagulation for survival is even less clear in our study, since we have been using these drugs only in recent years; however, although not significantly so, PPH patients on anticoagulants tended to have longer mean survival, and other studies12, 15 discussed earlier, seems to be associated with the hemodynamic profile of the patient at diagnosis. Indeed, PPH patients surviving more than 5 years in our study had lower PAP, PVRI, and RAP and had higher cardiac index at initial catheterization than those patients who died (see Table 5 ). Thus, our study supports the importance of the hemodynamic profile of PPH patients at diagnosis as one of the major determinants of prognosis in PPH. This association between survival and hemodynamic profile at diagnosis, particularly that related to right ventricular function, has been established in other recent studies,3"13'394",42 and it is also supported by the results of the multivariate analysis of the present study.
There Although it now appears clear that the hemodynamic profile at diagnosis is an important determinant of prognosis in PPH, an important and unsolved question regarding this association is whether a "good hemodynamic profile" at diagnosis reflects a different form or only a different stage of the disease. 18 We believe that the hemodynamic profile at diagnosis does not reflect only a different stage of the disease, on the basis of three important observations: (1) In the present and other studies,2"4'20 the period of time between initial symptoms and diagnosis (lag time) has been highly variable, and all of these studies have shown no correlation between this lag time and hemodynamic profile at diagnosis. (2) We had the opportunity to follow the clinical and hemodynamic evolution of some patients for 10 years or longer. During this period of time, these patients showed no evidence of significant deterioration, and 10 years from diagnosis is, in our opinion, a period of time long enough to see different stages of a disease such as PPH, for which a progressive course of deterioration and a poor prognosis had been previously established.2'812 (3) We investigated whether children with PPH in our series would have a better prognosis (ie, as a result of diagnosis at an earlier stage), and the answer was that survival expectancy in children with PPH is the same as that in the adult population (mean survival, 53.9 ±42.3 months in children versus 55.5 ±52.5 months in adults; P=NS).43 It appears, then, that in PPH there is a significant group of patients for whom the disease may follow a different, more benign, course.18,2'22 It is possible to speculate that these patients suffered an initial insult to their pulmonary circulation and that for some as yet unknown reason the damage to the pulmonary circulation was arrested or progressed at a slower rate (either because of the type and the dose of the insult and individual susceptibility or because the noxious stimulus was removed) and that these patients remain stable for many years with only a moderate degree of damage and hemodynamic involvement that allows them to have a better prognosis.
Projected Survival
One of the major objectives of the present study was to analyze the usefulness of the equation to predict prognosis in PPH patients recently proposed by the NIH multicenter study on PPH.20 Although there may be some limitations related to the design of the present study, the number of patients involved and the availability of reliable baseline hemodynamic measurements and long-term follow-up make it attractive to test the proposed equation in a different PPH patient population.
Despite the highly variable clinical course of the disease, it is remarkable how the equation was able to individually predict the survival of our PPH patients, with positive predictive values at 1, 2, and 3 years of 87%, 91%, and 89%, respectively. This finding reflects the facts that in our PPH patients, as well as in those of the NIH study, survival is determined in large part by the hemodynamic profile at diagnosis and that prognosis is particularly associated with those variables that assess right ventricular function. The close correlation between predicted and real survival found in the group of PPH patients without vasodilator treatment (Fig 5) also supports this concept, because the baseline hemodynamic profile in this group resembles that of the patients in the NIH multicenter study from which the equation was derived. There were, of course, a few instances in the group as a whole in which the equation underestimated the survival of some of the patients. This finding is expected because we are dealing with a younger population and because it is difficult to assess the influence that certain therapeutic interventions may have had on survival.
The formula, on the other hand, was relatively unable to predict deaths in our PPH patients. This may be a serious limitation of the equation, since it might be very important to identify which patients are at risk of death in the following year. There are, however, some considerations to make in this regard. First, it is important to stress that in assessment of deaths by the equation, only those values below 0.5 were considered, and this may be a very rigid criterion. The 7 patients who died during the first year in our study and who were not identified by the equation had a mean survival estimate of only 0.62±0.1, and in half of them the survival estimates were just above 0.5. Accordingly, the equation was indeed giving these patients low chances to survive the first year. Second, besides progressive hemodynamic deterioration, there are other forms of death in PPH patients that are not likely to be detected by the equation; for instance, sudden death is a recognized form of death in PPH patients. Also, death in PPH may be related to other causes (ie, diseases and/or interventions) that are independent but are aggravated by PPH.
On the basis of these results, we conclude that the proposed equation has a high sensitivity and a relatively low specificity to predict survival in PPH. To improve this specificity it may be necessary to increase the limits of poor prognosis and not to take into account only the strict limits of below and above 0.5 chance of survival. Also, the precise and reliable application of a given value to individual patients must be accompanied by a more complete
